Table 4.

Effect of regenerating agents RG1503 and RG1192 on production of collagen types and on the relative production of collagen types in intestinal fragments from patients with Crohn’s disease (CD)

	Collagen production (102 dpm hydroxy (3H) proline/mg collagen) (collagen type production as % of total collagen production)
	Collagen I	Collagen III	Collagen V
Control group	1300 (180)	290 (40)	80 (10)
% of total collagen	77.8 (10.4)	17.4 (2.4)	4.8 (0.6)
CD group	3840 (580)***	1800 (280)***	390 (60)***
% of total collagen	63.6 (9.6)	29.8 (4.6)*	6.4 (0.9)
CD group+RG1503	2260 (360)*†	430 (70)†††	260 (50)**†
% of total collagen	76.6 (11.5)	14.6 (1.9)††	8.8 (1.5)*
CD group+RG1192	3750 (450)***	690 (100)**††	230 (40)**†
% of total collagen	79.9 (13.2)	14.8 (2.2)††	5.2 (0.7)
CD-GC group	2430 (370)*	910 (140)**	240 (40)**
% of total collagen	67.9 (10.3)	25.4 (3.8)	6.8 (1.0)
CD-GC group+RG1503	1900 (280)	230 (40)‡‡‡	160 (30)*
% of total collagen	82.9 (12.5)	10.9 (1.7)‡‡	6.9 (1.1)
CD-GC group+RG1192	2330 (350)*	440 (80)‡‡	100 (20)‡‡
% of total collagen	81.1 (11.7)	3.4 (0.5)	15.5 (3.0)‡

Control, CD, and CD-GC groups as described in table 1 ▶.

RGTA treatment of normal intestinal tissue (control group) did not significantly change collagen type production (data not shown). The percentage of collagen type production compared with total collagen production was calculated from absolute values.

*p<0.05, **p<0.01, ***p<0.001 compared with the control group.

†p<0.05, ††p<0.01, †††p<0.001 between RGTA treatment and no RGTA treatment of specimens from the CD group.

‡p<0.05, ‡‡p<0.01, ‡‡‡p<0.001 between RGTA treatment and no RGTA treatment of specimens from the CD-GC group.